Subgroup analysis of patients with avid ipsilateral axillary lymph nodes post-vaccination
| Weeks post-vaccination | Male | Female | P value |
|---|---|---|---|
| <6 | 27/78 (35%) | 39/76 (51%) | 0.04 |
| ≥6 | 3/20 (15%) | 5/30 (17%) | 0.88 |
| Aged <65 years | Aged ≥65 years | ||
| <6 | 29/53 (55%) | 37/101 (37%) | 0.03 |
| ≥6 | 5/13 (38.5%) | 3/37 (8%) | 0.01 |
| Pfizer-BioNTech | Oxford-AstraZeneca | ||
| <6 | 14/42 (33%) | 19/36 (53%) | 0.08 |
| ≥6 | 4/20 (20%) | 2/7 (29%) | 0.64 |